Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda.
Abstract: The most prevalent Nucleoside Reverse Transcriptase Inhibitor (NRTI) mutations were M184V/I (67.3%), K219/Q/E (22.6%) and K65R (21.1%).
Discussion: However, M184V/I (67 (55.8%), p = 0.015), Y188L (9 (100%), p = 0.008) and TAMs (44 (51.8%), p = 0.011) were noted more in subtype A, but the number of occurrence of these mutations could not affect the overall association, therefore the study finds these individual mutation observations statistically irrelevant.
Discussion: The high prevalence of M184V might be attributed to the continued usage of lamivudine as a backbone in all regimens in Uganda and all over sub-Saharan since the presence of this mutation reduces the viral replicative fitness and increases susceptibil
HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.
Abstract: Antiretroviral resistance was detected in 21.5% of 93 pol sequences analyzed, with the M184I/V and K103N mutations that confer high-level resistance to NRTI and NNRTI, respectively, being the most frequent mutations.
Result: Among the 7 cases with NRTI mutations, the most common was M184I/V, which is known to confer high-level resistance to both emtricitabine (FTC) and 3TC.
Table: M184V
The S68G polymorphism is a compensatory mutation associated with the drug resistance mutation K65R in CRF01_AE strains.
Discussion: reported that mutations at position 68 followed the initial selection for K65R and M184 V mutations.
High resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_AG in Ghana and on antiretroviral therapy.
Discussion: M184 V also increases susceptibility to Zidovudine, Stavudine, and Tenofovir, and is associated with a clinically significant reduction in HIV-1 replication in vivo.
Discussion: Due to the decrease in susceptibility, patients infected with HIV-1 with the M184 V mutation continue treatment with Lamivudine, resulting in continuous exposure, and consequently, higher frequency of the mutation.
Discussion: Supplementary Digital Content 3) has been shown previously.M184 V mutation causes high-level resistance to Lamivudine, and therefore the high frequency of the mutation observed in this study is not unusual since the drug is the most common NRTI in use in Ghana.
Discussion: The predominance of M184 V and D67N among mutations associated with resistance to
M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients.
PMID: 32065630
2020
The Journal of antimicrobial chemotherapy
Abstract: BACKGROUND: M184V/I NRTI resistance mutations can be selected by either lamivudine/emtricitabine or abacavir.
Abstract: CONCLUSIONS: M184V/I as a unique NRTI resistance mutation, regardless of possible selection by regimens containing lamivudine/emtricitabine or abacavir, does not affect the virological response of well-controlled patients who switched to abacavir/lamivudine/dolutegravir for at least 12 months.
Abstract: OBJECTIVES: We assessed the efficacy of abacavir/lamivudine/dolutegravir when used in HIV-infected pretreated patients with an undetectable VL who previously harboured M184V/I as a unique NRTI resistance mutation in a genotypic resistance test and had no resistance to
Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine.
Abstract: Additionally, we experimentally simulated previously reported ETV/3TC resistance for HBV using HIVY115F/F116Y/Q151M with F160M/M184V (L180M/M204V in HBV RT) substituted.
Abstract: Structural analysis of RTY115F/F116Y/Q151M/F160M/M184V:DNA:3TC-TP also demonstrated that the loosely bound 3TC-TP is misaligned at the active site to prevent a steric clash with the side chain gamma-methyl of Val184.
Introduction: 3TC is also approved as an anti-HIV-1 agent, and M184V in HIV-1 RT, which co
Natural polymorphisms in HIV-1 CRF01_AE strain and profile of acquired drug resistance mutations in a long-term combination treatment cohort in northeastern China.
Result: Result: Nine known DRMs (K65R, V106 M, Y115F, V179 T/E/D, Y181C, M184 V, and G190S) and two potential new DRMs (V75 L and L228R) were demonstrated to be under positive selection pressure (Ka/Ks > 1, LOD > 2).
Result: The NRTI-associated DRMs detected at TF time point in descending order included K65R (57.1%), M184 V/I (47.6%), S68G (26.2%), A62V (14.3%), K70E/R (9.5%), and Y115F (9.5%).
High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment.
PMID: 32105319
2020
The Journal of antimicrobial chemotherapy
Table: M184V
HIV-1 reverse transcriptase and protease mutations for drug-resistance detection among treatment-experienced and naive HIV-infected individuals.
Abstract: M46I and I47V were the most common mutations for
Result: The most common mutations were M46I and I47V for PIs, M184V for NRTIs, and K103N/S for NNRTIs (Table 6).
Table: M184V
Discussion: M46I and I47V were the most frequent mutations for PIs; M184V was the most common mutation for the NRTIs, and K103N/S was the most common mutation for NNRTIs.
HIV mutation literature information.
PMID: 
2020
AIDS research and therapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT